Emerging drugs for acute graft-versus-host disease

Bibliography

• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007;25:139-70
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006;43(1):3-10
   PubMed Web of Science ®Google Scholar
• Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95(9):2754-9
   PubMed Web of Science ®Google Scholar
• Anderson BE, Taylor PA, McNiff JM, et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 2008;111(10):5242-51
   PubMed Web of Science ®Google Scholar
• Murai M, Yoneyama H, Ezaki T, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003;4(2):154-60
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004;104(4):961-8
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003;18(3):367-79
   PubMed Web of Science ®Google Scholar
• Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007;7(5):340-52
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol 2005;174(4):1841-50
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371(9624):1579-86
   PubMed Web of Science ®Google Scholar
• Granell M, Urbano-Ispizua A, Pons A, et al. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood 2008;112(10):4337-42
   PubMed Web of Science ®Google Scholar
• Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006;107(10):4189-93
   PubMed Web of Science ®Google Scholar
• Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001;21(4):258-63
   PubMed Web of Science ®Google Scholar
• Korngold R, Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med 1982;155(3):872-83
   PubMed Web of Science ®Google Scholar
• Zhang Y, Joe G, Hexner E, et al. Host-reactive CD8 + memory stem cells in graft-versus-host disease. Nat Med 2005;11(12):1299-305
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA. Regulatory T cells. Biol Blood Marrow Transplant 2005;11(2 Suppl 2):46-9
   PubMed Web of Science ®Google Scholar
• Zeng D, Lewis D, Dejbakhsh-Jones S, et al. Bone marrow NK1.1(-) and NK1.1( + ) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999;189(7):1073-81
   PubMed Web of Science ®Google Scholar
• Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005;353(13):1321-31
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92(7):2303-14
   PubMed Web of Science ®Google Scholar
• Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4 + CD25 + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006;108(1):390-9
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991;324(10):667-74
   PubMed Web of Science ®Google Scholar
• van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002;2(4):273-81
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006;203(8):2021-31
   PubMed Web of Science ®Google Scholar
• Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versus-host disease. Blood 2005;105(11):4191-9
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5(10):987-95
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11(12):945-56
   PubMed Web of Science ®Google Scholar
• Pasquini MCWZ, Schneider L. Current use and outcome of hematopoietic stem cell transplantation: part I- CIBMTR Summary Slides, 2007. CIBMTR Newsletter [Serial Online] 2007;13(2):5-9; http://www.cibmtr.org/PUBLICATIONS/Newsletter/index.html
   Google Scholar
• Sullivan KM. Graft-vs.-host disease. In: Blume K, Forman SJ, Appelbaum FR, editors, Thomas' Hematopoietic Cell Transplantation: Blackwell Publishing Ltd 2004. p. 635-64
   Google Scholar
• Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005;17(5):517-25
   PubMed Web of Science ®Google Scholar
• Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005;366(9487):733-41
   PubMed Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49(4):511-33
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989;320(13):828-34
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985;65(6):1325-34
   PubMed Web of Science ®Google Scholar
• Irle C, Deeg HJ, Buckner CD, et al. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 1985;9(10):1255-61
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988;71(2):293-8
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989;73(6):1729-34
   PubMed Web of Science ®Google Scholar
• Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986;314(12):729-35
   PubMed Web of Science ®Google Scholar
• Weaver CH, Clift RA, Deeg HJ, et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplant 1994;14(6):885-93
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77(7):1423-8
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Rondelli R, et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000;95(5):1572-9
   PubMed Web of Science ®Google Scholar
• Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993;329(17):1225-30
   PubMed Web of Science ®Google Scholar
• Ruutu T, Volin L, Parkkali T, et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000;96(7):2391-8
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Lin D, Leisenring W, et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997;89(10):3880-7
   PubMed Web of Science ®Google Scholar
• Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000;96(6):2062-8
   PubMed Web of Science ®Google Scholar
• Mohty M, de Lavallade H, Faucher C, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004;34(6):527-30
   PubMed Web of Science ®Google Scholar
• Bornhauser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26(2):119-25
   PubMed Web of Science ®Google Scholar
• Kasper C, Sayer HG, Mugge LO, et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 2004;33(1):65-9
   PubMed Web of Science ®Google Scholar
• Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001;27(12):1255-62
   PubMed Web of Science ®Google Scholar
• Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;34(7):621-5
   PubMed Web of Science ®Google Scholar
• Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005;11(7):495-505
   PubMed Web of Science ®Google Scholar
• Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005;35(11):1089-93
   PubMed Web of Science ®Google Scholar
• Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003;102(5):1601-5
   PubMed Web of Science ®Google Scholar
• Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007;109(7):3108-14
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6):641-50
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8(7):377-86
   PubMed Web of Science ®Google Scholar
• Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984;44(11):5156-60
   PubMed Web of Science ®Google Scholar
• Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85(10):2742-6
   PubMed Web of Science ®Google Scholar
• Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996;195(2):129-39
   PubMed Web of Science ®Google Scholar
• O'Donnell P, Luznik L, Symons H, et al. Favorable outcome of patients with relapsed hodgkin lymphoma (HL) after nonmyeloablative hematopoietic cell transplantation (NM-HCT) using related haploidentical donors. Blood 2006;108:894a-5a
   Google Scholar
• Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000;26(1):69-76
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100(9):3121-7
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002;99(12):4357-63
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002;100(5):1619-27
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007;21(7):1387-94
   PubMed Web of Science ®Google Scholar
• Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005;35(3):225-31
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Ehninger G, Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells–clinical problems and current challenges. Leuk Lymphoma 2004;45(3):447-53
   PubMed Web of Science ®Google Scholar
• Champlin RE, Passweg JR, Zhang MJ, et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 2000;95(12):3996-4003
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Peceny R, Steckel N, et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003;101(2):446-53
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21(6):543-51
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Roosnek E, Mermillod B, et al. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 2006;12(1):102-10
   PubMed Web of Science ®Google Scholar
• Ho VT, Kim HT, Li S, et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant 2004;34(11):987-94
   PubMed Web of Science ®Google Scholar
• Elhasid R, Arush MB, Zaidman I, et al. Safe and efficacious allogeneic bone marrow transplantation for nonmalignant disorders using partial T cell depletion and no posttransplantation graft-versus-host-disease prophylaxis. Biol Blood Marrow Transplant 2007;13(3):329-38
   PubMed Web of Science ®Google Scholar
• Alyea EP, Weller E, Fisher DC, et al. Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2002;8(11):601-7
   PubMed Web of Science ®Google Scholar
• Davies JK, Koh MBC, Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant 2004;10(4):259-68
   PubMed Web of Science ®Google Scholar
• Kalaycio M, Rybicki L, Pohlman B, et al. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens. Bone Marrow Transplant 2005;35(3):247-52
   PubMed Web of Science ®Google Scholar
• Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007;109(1):374-82
   PubMed Web of Science ®Google Scholar
• Solomon SR, Mielke S, Savani BN, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106(3):1123-9
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18(4):295-304
   PubMed Web of Science ®Google Scholar
• Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998;92(7):2288-93
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8(7):387-94
   PubMed Web of Science ®Google Scholar
• Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007;109(10):4557-63
   PubMed Web of Science ®Google Scholar
• McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998;115(1):28-35
   PubMed Web of Science ®Google Scholar
• Bertz H, Afting M, Kreisel W, et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999;24(11):1185-9
   PubMed Web of Science ®Google Scholar
• Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109(10):4119-26
   PubMed Web of Science ®Google Scholar
• Fleig WE. [Topical steroids in chronic inflammatory bowel diseases]. Der Internist 1997;38(12):1154-9
   PubMed Web of Science ®Google Scholar
• Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000;6(4A):441-7
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95(1):83-9
   PubMed Web of Science ®Google Scholar
• Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004;104(5):1559-64
   PubMed Web of Science ®Google Scholar
• Alousi AWD, Logan B, Meade JB, et al. BMT CTN 0302: A phase II randomized trial evaluating etanercept, mycophenolate mofetil, denileukin diftitox, and pentostatin in combination with corticosteroids in 180 patients with newly diagnosed a GVHD [abstract 55]. ASH Annual Meeting Abstracts 2008;112:112-3
   Google Scholar
• Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease: past, present and future. Pediatr Transplant 2003;7(Suppl 3):19-31
   PubMed Web of Science ®Google Scholar
• Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104(3):649-54
   PubMed Web of Science ®Google Scholar
• Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003;74(2):119-24
   PubMed Web of Science ®Google Scholar
• Antin JH, Chen AR, Couriel DR, et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004;10(10):655-68
   PubMed Web of Science ®Google Scholar
• Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008;111(4):2470-5
   PubMed Web of Science ®Google Scholar
• Bay J-O, Dhédin N, Goerner M, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005;80(6):782-8
   PubMed Web of Science ®Google Scholar
• Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996;88(3):824-30
   PubMed Web of Science ®Google Scholar
• Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(4):1224-6
   PubMed Web of Science ®Google Scholar
• Basara N, Kiehl MG, Blau W, et al. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transpl Proc 2001;33(3):2121-3
   PubMed Web of Science ®Google Scholar
• Epstein J, Bealmear PM, Kennedy DW, et al. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin. Exp Hematol 1986;14(9):845-9
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005;23(12):2661-8
   PubMed Web of Science ®Google Scholar
• Dorr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002;54(1):245-51
   PubMed Web of Science ®Google Scholar
• Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58(5):933-9
   PubMed Web of Science ®Google Scholar
• Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108(9):3216-22
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418(6893):41-9
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284(5411):143-7
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11(5):389-98
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439-41
   PubMed Web of Science ®Google Scholar
• Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81(10):1390-7
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Isola L, Bahceci E, et al. Phase II Trial of ProchymalTM (Ex-Vivo Cultured Adult Human Mesenchymal Stem Cells) and Corticosteroids as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD). ASH Annual Meeting Abstracts 2006;108(11):3231
   Google Scholar
• Osiris Theraputics Provides Update on Phase II Trial Evaluating PROCHYMAL (TM) for the Treatment of Acute Graft vs. Host Diaease In: Elchin E, editor, Baltimore: Business Wire
   Google Scholar
• Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant 2008;42(9):609-17
   PubMed Web of Science ®Google Scholar
• Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(1 Suppl 2):7-12
   PubMed Web of Science ®Google Scholar
• Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001;27(10):1059-64
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991;77(8):1821-8
   PubMed Web of Science ®Google Scholar